Download Full eBooks in PDF
Medicaid Prescription Drug Reimbursement Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Medicaid Prescription Drug Reimbursement book. This book definitely worth reading, it is an incredibly well-written.
Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
Publisher : Unknown
Page : 620 pages
File Size : 53,9 Mb
Release : 2005
Category : Medical
ISBN : UVA:X005106517
Author : Melvina Ford
Publisher : DIANE Publishing
Page : 41 pages
File Size : 42,5 Mb
Release : 1991
Category : Insurance, Pharmaceutical services
ISBN : 9781428933552
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies
Publisher : National Academies Press
Page : 235 pages
File Size : 47,8 Mb
Release : 2018-03-01
Category : Medical
ISBN : 9780309468084
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author : F. Randy Vogenberg
Publisher : ASHP
Page : 169 pages
File Size : 50,9 Mb
Release : 2006
Category : Business & Economics
ISBN : 9781585281084
As a health system pharmacist dealing with health care reform initiatives and accountable care organizations, it is important to have a fundamental understanding of health care reimbursement that has a focus on pharmacy. Understanding Pharmacy Reimbursement is the essential resource that allows you to more effectively deal with the rapidly changing and constantly emerging reimbursement issues over the next few years.
Author : United States. Congress. House. Committee on Ways and Means. Subcommittee on Health
Publisher : Unknown
Page : 208 pages
File Size : 42,6 Mb
Release : 1988
Category : Medicare
ISBN : PSU:000013399641
Author : Institute of Medicine,Board on Health Sciences Policy,Committee on Accelerating Rare Diseases Research and Orphan Product Development
Publisher : National Academies Press
Page : 442 pages
File Size : 47,8 Mb
Release : 2011-04-03
Category : Medical
ISBN : 9780309158060
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
Publisher : Unknown
Page : 112 pages
File Size : 44,7 Mb
Release : 2005
Category : Business & Economics
ISBN : UVA:X005108415
Author : Congressional Research Congressional Research Service
Publisher : CreateSpace
Page : 66 pages
File Size : 40,6 Mb
Release : 2014-11-07
Category : Electronic
ISBN : 1503177084
Medicaid is a federal-state entitlement program that pays for health care and related services on behalf of certain low-income individuals. Prescription drugs are an optional Medicaid benefit and all states cover outpatient drugs. States can create formularies, or lists of preferred drugs, but federal rules tend to result in comprehensive coverage, even for beneficiaries enrolled in Medicaid managed care plans. Pharmaceutical manufacturers that voluntarily participate in Medicaid are required to pay rebates to states on covered outpatient drugs, which help Medicaid receive manufacturers' lowest or best price. States then share the rebate they receive from pharmaceutical manufacturers with the federal government. In determining the amount of rebate, Medicaid law distinguishes between the following two drug types: (1) single source drugs (brand-name drugs) and innovator multiple source drugs (brand-name drugs that now have generic competition); and (2) all other, non-innovator, multiple source (generic) drugs. Rebates for the first category of drugs-drugs still under patent or those once covered by patents-have two components: a basic rebate and an additional rebate. In addition to basic and additional rebates, most states negotiate supplemental rebates with drug manufacturers, by offering to encourage use of a manufacturer's product in exchange for a price concession (rebate). States, through retail pharmacies, purchase drugs on behalf of Medicaid beneficiaries. Medicaid pharmacy reimbursement has two components: a payment to cover the cost of the pharmacy buying the drug (ingredient cost) and a payment for the pharmacist's services in filling a prescription (dispensing fee). States set reimbursement for both ingredient costs and dispensing fees.
Author : Anonim
Publisher : U.S. Government Printing Office
Page : 94 pages
File Size : 54,6 Mb
Release : 1998
Category : Business & Economics
ISBN : PURD:32754071785707
Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
Publisher : Unknown
Page : 684 pages
File Size : 51,6 Mb
Release : 2005
Category : Medical
ISBN : STANFORD:36105050386221
Author : Anonim
Publisher : Unknown
Page : 234 pages
File Size : 50,8 Mb
Release : 2000
Category : Drugs
ISBN : STANFORD:36105028431273
On October 25,1999, the President directed the Secretary of Health and Human Services to study prescription drug costs and trends for Medicare beneficiaries. He asked that the study investigate: price differences for the most commonly used drugs for people with and without coverage; drug spending by people of various ages, as a percentage of income and of total health spending; and trends in drug expenditures by people of different ages, as a percentage of income and of total health spending. This report is the Department's response to that request. It represents the work of individuals and agencies throughout the Department, including the Agency for Healthcare Research and Quality (AHRQ), the Food and Drug Administration (FDA), the Health Care Financing Administration (HCFA), and the Office of the Assistant Secretary for Planning and Evaluation (ASPE).
Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
Publisher : Unknown
Page : 128 pages
File Size : 51,8 Mb
Release : 2005
Category : Business & Economics
ISBN : STANFORD:36105050402150
Author : United States. Congress. Senate. Committee on Finance. Subcommittee on Health for Families and the Uninsured
Publisher : Unknown
Page : 352 pages
File Size : 48,9 Mb
Release : 1991
Category : Drugs
ISBN : PSU:000018290417
Author : Institute of Medicine,Division of Health Care Services,VA Pharmacy Formulary Analysis Committee
Publisher : National Academies Press
Page : 280 pages
File Size : 53,5 Mb
Release : 2000-10-03
Category : Medical
ISBN : 9780309183536
The VA National Formulary generated controversy, which motivated congressional scrutiny and a directive to the VA to commission this report reviewing the experience with the National Formulary and formulary system. This Institute of Medicine committee was pleased to assist the Congress with this review, in part because the committee saw in the VHA example an opportunity to understand and anticipate problems that all publicly funded programs are likely to encounter in this new age of pharmaceuticals. The Congress asked the committee to review the restrictiveness of the National Formulary, its impact on the costs and quality of care in the VHA, and how it compared to formularies and drug management practices in the private sector and in other public programs, especially Medicaid. Detailed in the pages that follow, the committee's findings and conclusions on these questions are, the committee believes, highly instructive, though not always in the ways that we anticipated.
Author : United States. Social and Rehabilitation Service
Publisher : Unknown
Page : 462 pages
File Size : 48,8 Mb
Release : 1975
Category : Medicaid
ISBN : STANFORD:36105214593894
